Contact
Please use this form to send email to PR contact of this press release:
Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data
TO:
Please use this form to send email to PR contact of this press release:
Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data
TO: